An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Cybin to Participate in the Oppenheimer 33rd Annual Healthcare Conference
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
Cybin Inc. (AMEX:CYBN) announced that CEO Doug Drysdale will participate in a virtual fireside chat during the Oppenheimer 33rd Annual Healthcare Conference from March 13-15, 2023. The live webcast is scheduled for March 14, 2023, at 12:40 p.m. ET. Interested parties can click here to access the live stream. Cybin is committed to developing safe, effective therapeutics for mental health issues and operates across various countries, focusing on innovative drug delivery and drug discovery for psychedelic-based therapies.
Positive
None.
Negative
None.
TORONTO--(BUSINESS WIRE)--
Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) (“Cybin” or the “Company”), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics® is pleased to announce that Doug Drysdale, Cybin’s Chief Executive Officer, will participate in a virtual fireside chat at the Oppenheimer 33rd Annual Healthcare Conference taking place on March 13-15, 2023.
Mr. Drysdale’s fireside chat will be webcast live on Tuesday, March 14, 2023 at 12:40 p.m. ET. To listen to the event, please click here to access the webcast. The archived webcast will also be available on the Company’s investor relations website on the Events & Presentations page.
About Cybin
Cybin is a leading ethical biopharmaceutical company, working with a network of world-class partners and internationally recognized scientists, on a mission to create safe and effective therapeutics for patients to address a multitude of mental health issues. Headquartered in Canada and founded in 2019, Cybin is operational in Canada, the United States, the United Kingdom, the Netherlands and Ireland. The Company is focused on progressing Psychedelics to Therapeutics by engineering proprietary drug discovery platforms, innovative drug delivery systems, novel formulation approaches and treatment regimens for mental health disorders.
Investor & Media Contact:
Leah Gibson Vice President, Investor Relations & Strategic Communications Cybin Inc. irteam@cybin.com – or – media@cybin.com
Gabriel Fahel Chief Legal Officer
Cybin Inc. 1-866-292-4601
Source: Cybin Inc.
FAQ
What event will Cybin's CEO participate in during March 2023?
CEO Doug Drysdale will participate in the virtual fireside chat at the Oppenheimer 33rd Annual Healthcare Conference from March 13-15, 2023.
When is Cybin's CEO's fireside chat scheduled?
The fireside chat is scheduled for March 14, 2023, at 12:40 p.m. ET.
Where can I watch the Cybin fireside chat?
The fireside chat will be available for live streaming at the Oppenheimer Conference; access it here.
What is Cybin's primary focus as a biopharmaceutical company?
Cybin focuses on progressing Psychedelics to Therapeutics for addressing various mental health issues, utilizing innovative drug discovery and delivery methods.
What countries does Cybin operate in?
Cybin operates in Canada, the United States, the United Kingdom, the Netherlands, and Ireland.
